NanoVibronix, Inc. (NASDAQ: NAOV) has changed its corporate name to ENvue Medical and announced a strategic pivot to the enteral feeding market, with a new Nasdaq ticker symbol to be adopted shortly. The company’s ENvue® feeding‑tube placement system is positioned as the core growth platform and will drive future revenue and profitability.
The company’s financial trajectory shows a clear turnaround. In Q3 2024, NanoVibronix generated $376 k in revenue and posted a net loss of $998 k. By Q3 2025, revenue had risen to $722 k and the company reported a net income of $510 k, a swing of $1.21 million in operating results that underscores the impact of the ENvue platform and disciplined cost management.
The ENvue system, which received FDA 510(k) clearance in 2019, is currently deployed in 38 U.S. hospitals. The acquisition of ENvue Medical Holdings was completed in February 2025 and the system was fully integrated into NanoVibronix’s operations in early 2025, giving the company a ready‑to‑scale product in a growing market.
The U.S. enteral feeding market is projected to reach $1.8 billion by 2030, driven by an aging population and rising prevalence of chronic conditions that require long‑term nutrition support. ENvue’s electromagnetic guidance technology offers a competitive advantage by reducing misplacement risk and potentially eliminating the need for X‑ray confirmation, positioning the company to capture market share from established players such as Abbott, Nestlé, and Nutricia (Danone).
NanoVibronix is also evaluating strategic alternatives for its legacy pain and wound‑therapy assets, PainShield and UroShield. Management indicated that divestitures or partnerships could free capital and focus resources on the high‑growth enteral feeding segment, while the company continues to monitor the performance of these legacy lines.
CEO Doron Besser, who joined the company in June 2025, said, “Our strategy is now focused on scaling hospital utilization, strengthening our commercial footprint, and building a comprehensive enteral‑feeding ecosystem around ENvue.” He added that the rebranding marks ENvue Medical’s first entry into the Louisiana market and reflects growing clinical interest in electromagnetic guidance technology for enteral access.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.